Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (59.13 KB, 3 trang )
TherapeuticOptionsforPatientsWith
CancerTreatment-RelatedCardiotoxicity
Somepractitionersinthefieldofcardio-oncologysupportthenotionthatall
patientsexposedtocancertreatmentshouldbeconsideredAmericanCollegeof
Cardiology/AmericanHeartAssociationstageAheartfailure,withthegoal
beingtopreventprogressiontostagesBtoD.15
MedicalTherapy
Adultsshouldreceivestandardguideline-directedheartfailuretherapy,76
supplementedbycardio-oncology–specificguidelinesthatinclude
recommendationsfortherapyinresponsetochangesinimagingandserum
biomarkers,symptomaticheartfailure,anddirectedbyspecificchemotherapy
exposures.16AlthoughCTCisnotcoveredspecifically,therearenowpediatric
guidelinesformanagementofcardiomyopathyandheartfailure.77
AdvancedHeartFailureTherapy
Whenstandardoraltherapiesareinsufficienttomanageheartfailure,patients
withCTCmayprogresstotheneedforinotropicormechanicalsupportoreven
considerationofhearttransplantation.Activeneoplasmandongoing
chemotherapyand/orradiotherapyarecontraindicationstotransplantationat
mostcenters.Transplantationcanbeconsideredifrecurrenceofthetumoris
deemedtobelow,thereisanegativeworkupforthepresenceofmetastases,and
otherconsiderationsthatincludetumortypeandresponsetotherapy.78Thereis
noobjectivetimeaftertherapyrequiredbeforelistingfortransplantation.
ReportsofhearttransplantationtotreatCTCinchildrenextendback20
years,79andarecentreviewofdatafromthePediatricHeartTransplantStudy
showthat,forappropriatelyselectedpatients,thereisnodifferenceinlong-term
graftsurvivalwhencomparedwithotherformsofdilatedcardiomyopathy.80For
patientsunabletowait,orforwhomitisnotappropriatetolistfor
transplantation,mechanicalcirculatorysupportmaybeoffered.Ifthe
mechanismofdysfunctionisbelievedtobetemporaryorreversible,short-or